Results

1–10 of 165 results for Diabetic Macular Edema

Population Pharmacokinetics and Safety of OPT-302 an Anti-VEGF-C--D Trap in Patients With Retinal Vascular Diseases
Dante Joseph Pieramici, MD
Annual Meeting Talks
2023
Pooled Safety Analysis of Aflibercept 8 mg in the CANDELA PHOTON and PULSAR Trials
Philip J. Ferrone, MD, FASRS
Annual Meeting Talks
2023
Intended vs Actual Intervals Between Intravitreal Anti-VEGF Injections and Assessment of Treatment Delays
Christina Y Weng, MD, MBA, FASRS
Annual Meeting Talks
2023
Early Treatment Patterns and Outcomes in Patients With Neovascular Age-Related Macular Degeneration Initiating Faricimab: The FARETINA-AMD Study
Theodore Leng, MD, MS, FASRS
Annual Meeting Talks
2023
Early Treatment Patterns and Outcomes in Patients With Diabetic Macular Edema Treated With Faricimab: FARETINA-DME Study
Durga Borkar, MD
Annual Meeting Talks
2023
Time to Retinal Fluid Control With Faricimab vs Aflibercept in Patients With DME in the Phase 3 YOSEMITE/RHINE Trials
Aleksandra V. Rachitskaya, MD, FASRS
Annual Meeting Talks
2023
Faricimab Reduces Macular Leakage vs Aflibercept in Patients With DME
Eric Nudleman, MD, PhD
Annual Meeting Talks
2023
Impact of Faricimab vs Aflibercept on Epiretinal Membrane Formation Over 2 Years in Eyes With DME in the YOSEMITE/RHINE Phase 3 Trials
Glenn J. Jaffe, MD
Annual Meeting Talks
2023
Efficacy and Safety of CT-P42 Compared to Reference Aflibercept (AFL) in Diabetic Macular Edema (DME): 24-Week Results From the Phase 3 CT-P42 3.1 Study
David M. Brown, MD
Annual Meeting Talks
2023
Tarcocimab Tedromer (KSI-301) Anti-VEGF Antibody Biopolymer Conjugate for DME: First-Time Efficacy, Durability and Safety Results of the GLEAM and GLIMMER Phase 3 studies
Charles C Wykoff, MD, PhD, FASRS
Annual Meeting Talks
2023